Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2011-03-08 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
Director's Dealing 2011
Director's Dealing
2011-03-08 English
Board/Management Information 2011
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the appointment of a new Vice President of Strategic Business Development, which is a change in senior management. There are no financial statements or detailed financial data included, and the document is relatively short (2288 characters). This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2011-03-08 English
Director's Dealing 2011
Director's Dealing
2011-03-04 English
Director's Dealing 2011
Director's Dealing
2011-03-04 English
Director's Dealing 2011
Director's Dealing
2011-03-02 English
Investor Presentation 2011
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NeoStem, Inc. It includes a Regulation FD Disclosure about a slide presentation attached as Exhibit 99.1. The text explicitly states that the slide presentation is intended for distribution to the investment community and is accessible on the company's website. The document does not contain financial statements or detailed financial analysis but rather a presentation material. The presence of a slide presentation and the nature of the disclosure align with an Investor Presentation filing. The document length is about 4809 characters, which is consistent with a typical 8-K filing containing a presentation. Therefore, the most appropriate classification is Investor Presentation (IP).
2011-03-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.